1 not yet recruiting, 1 recruiting, 1 unknown. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Olverembatinib: new trials by email Literature Review of Olverembatinib trials Research Report on Olverembatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment Olverembatinib 20mg - Pharmacokinetic, Olverembatinib | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 48 | 2025-11-11 | 2025-12-23 |
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. olverembatinib - Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase | Phase 3 | Unknown | Shenzhen Second People's Hospital | 40 | 2022-07-01 | 2022-07-29 |
Leukemia, Myeloid, Chronic-Phase (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1)
olverembatinib (3) · blinatumomab (1)
Ascentage Pharma Group Inc. (1) · M.D. Anderson Cancer Center (1) · Shenzhen Second People's Hospital (1)
China (2) · United States (1)
Elias J Jabbour, MD (1) · Liyan Miao, M.D.,Ph.D. (1) · Weifeng Zhao, M.D.,Ph.D. (1) · Xin Du, Phd (1)